DA-007
Phase 3Small molecule
DA-007 is one of 23 small molecule programs targeting Alopecia. It is currently in Phase 3.
1
Indications
1
Total Trials
1
Active Trials
22
Competitors
Pipeline
Status by Indication[3][1]
Competition
Competitive Landscape
40 competitors in Alopecia
#DrugCompanyPhaseTrials
1Otezla
AmgenApproved
Trexall
Alnylam PharmaceuticalsApproved
Olumiant
Eli LillyApproved
Opzelura
PfizerApproved
Zolymbus
AbbVieApproved
Raptiva
RochePhase 2
Anzupgo
Alnylam PharmaceuticalsPhase 2
Cosentyx
NovartisPhase 2
Avodart
Akero TherapeuticsPhase 2
Rogaine
PfizerPhase 1
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Timeline
Expected Milestones
Clinical
Trials by Indication[1]
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for DA-007. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details
Drug Info
Quick Facts
- Modality
- Small molecule[2]
- Highest Phase
- Phase 3[1]
- Company
- AApplied Biology, Inc.